Adc Therapeutics Sa (ADCT)
$4.49
Live
Insights on Adc Therapeutics Sa
Increasing Revenue
Revenue is up for the last 2 quarters, 14.49M → 16.79M (in $), with an average increase of 13.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -47.11M → -85.03M (in $), with an average decrease of 39.7% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 320.1%
Performance
- $4.41$4.65$4.49
1.78%
Downside
Day's Volatility :5.16%
Upside
3.44%
- $0.36$6.04$4.49
91.98%
Downside
52 Weeks Volatility :94.04%
Upside
25.66%
Returns
| Period | Adc Therapeutics Sa | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 84.56% | 1.7% | 0.0% |
6 Months | 634.25% | 11.3% | 0.0% |
1 Year | 143.88% | 5.4% | 1.3% |
3 Years | -81.38% | 13.9% | -22.1% |
Highlights
Market Capitalization | 410.2M |
Book Value | - $1.8 |
Earnings Per Share (EPS) | -2.94 |
Wall Street Target Price | 10.2 |
Profit Margin | 0.0% |
Operating Margin TTM | -221.69% |
Return On Assets TTM | -24.54% |
Return On Equity TTM | -705.53% |
Revenue TTM | 69.6M |
Revenue Per Share TTM | 0.85 |
Quarterly Revenue Growth YOY | -75.9% |
Gross Profit TTM | 35.1M |
EBITDA | -164.8M |
Diluted Eps TTM | -2.94 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.39 |
EPS Estimate Next Year | -1.85 |
EPS Estimate Current Quarter | -0.5 |
EPS Estimate Next Quarter | -0.47 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 127.17%
Technicals Summary
Sell
Neutral
Buy
Adc Therapeutics Sa is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adc Therapeutics Sa | 13.81% | 634.25% | 143.88% | -81.38% | -83.88% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adc Therapeutics Sa | NA | NA | NA | -2.39 | -7.06 | -0.25 | NA | -1.8 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adc Therapeutics Sa | Buy | $410.2M | -83.88% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Prosight Management, LP
7.84%Goldman Sachs Group Inc
3.54%Citadel Advisors Llc
3.51%Millennium Management LLC
3.24%Bank of America Corp
1.85%Affinity Asset Advisors, LLC
1.23%
Corporate Announcements
Adc Therapeutics Sa Earnings
Adc Therapeutics Sa’s price-to-earnings ratio stands at None
Read More
Company Information
adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Organization | Adc Therapeutics Sa |
Employees | 273 |
CEO | Dr. Ameet Mallik M.B.A., M.S. |
Industry | Health Technology |
